PROLIDASE ACTIVITY AND OXIDATIVE STRESS IN BENIGN, PRE-MALIGNANT AND MALIGNANT ENDOMETRIAL LESIONS

Yıl 2023, , 195 - 200, 05.04.2023

Mesut Köse , Ayhan Vurmaz , Yasemin Çelik

https://doi.org/10.18229/kocatepetip.1105749

Öz

OBJECTIVE: The present study aims to investigate the prolidase activity, total oxidant status (TOS) and total anti-oxidant status (TAS) in women who have been diagnosed with benign, pre-malignant and malignant endometrial pathologies.
MATERIAL AND METHODS: Ninety women who underwent endometrial biopsy due to abnormal uterine bleeding were divided into three groups according to their histopathological findings: Benign endometrial pathology (n=65), endometrial hyperplasia (n=12) and endometrial cancer (n=13). These groups were compared with respect to oxidative stress markers and prolidase activity in serum and endometrial tissue.
RESULTS: When compared to the benign endometrial pathology group, the endometrium cancer group had significantly higher age, shorter height and higher incidences of menopause and positive family history for gynecological malignancy (p=0.001, p=0.023, p=0.001 and p=0.001). When compared to the benign endometrial pathology group, tissue prolidase activity was significantly higher in the endometrium hyperplasia and endometrium cancer groups (p=0.001 for both). However, tissue prolidase activity was statistically similar in the endometrial hyperplasia and endometrial cancer groups (p=0.166). All study groups had statistically similar serum prolidase activity, serum and tissue TOS, serum and tissue TAS, tissue malondialdehyde and glutathione values.
CONCLUSIONS: Prolidase activity in endometrial tissue has enhanced in pre-malignant and malignant endometrial lesions when compared to benign endometrial lesions. The assessment of prolidase activity in endometrial tissue might help to distinguish pre-malignant and malignant lesions in case histopathological characteristics are insufficient for the differentiation of endometrial lesions.

Anahtar Kelimeler

Biopsy, Endometrium cancer, Hhyperplasia, Oxidative stress, Prolidase activity

BENİGN, PRE-MALİGN VE MALİGN ENDOMETRİYAL LEZYONLARDA PROLİDAZ AKTİVİTESİ VE OKSİDATİF STRES

Öz

AMAÇ: Bu çalışmada benign, pre-malign ve malign endometrial patolojiler tanısı konan kadınlarda prolidaz aktivitesi, toplam oksidan durumu (TOS) ve toplam antioksidan durumu (TAS) araştırıldı.
GEREÇ VE YÖNTEM: Anormal uterin kanama nedeniyle endometriyal biyopsi yapılan doksan kadın histopatolojik bulgularına göre üç gruba ayrıldı: Benign endometrial patoloji (n=65), endometrial hiperplazi (n=12) ve endometrial kanser (n=13). Bu gruplar, serum ve endometriyal dokudaki oksidatif stres belirteçleri ve prolidaz aktivitesi açısından karşılaştırıldı.
BULGULAR: Benign endometrial patoloji grubu ile karşılaştırıldığında, endometrium kanserli grup anlamlı olarak daha yüksek yaş, daha kısa boy ve menopoz insidansı ve jinekolojik malignite açısından pozitif aile öyküsüne sahipti (p=0,001, p=0,023, p=0,001 ve p=0,001). Benign endometrial patoloji grubu ile karşılaştırıldığında, endometrium hiperplazisi ve endometrium kanseri gruplarında doku prolidaz aktivitesi anlamlı olarak daha yüksekti (her ikisi için p=0,001). Ancak doku prolidaz aktivitesi, endometriyal hiperplazi ve endometriyal kanser gruplarında istatistiksel olarak benzerdi (p=0,166). Tüm çalışma grupları istatistiksel olarak benzer serum prolidaz aktivitesi, serum ve doku TOS, serum ve doku TAS, doku malondialdehit ve glutatyon değerlerine sahipti.
SONUÇ: Endometriyal dokudaki prolidaz aktivitesi, benign endometrial lezyonlarla karşılaştırıldığında, pre-malign ve malign endometriyal lezyonlarda artmıştır. Endometriyal dokudaki prolidaz aktivitesinin değerlendirilmesi, histopatolojik özelliklerin endometriyal lezyonların ayırt edilmesi için yetersiz olması durumunda malign öncesi ve malign lezyonları ayırt etmeye yardımcı olabilir.

Anahtar Kelimeler

Biyopsi, Endometrium kanseri, Hiperplazi, Oksidatif stres, Prolidaz aktivitesi

Kaynakça

• 1. Matthews ML. Abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol Clin North. 2015;42(1): 103-15.
• 2. Singh S, Best C, Dunn S, Leyland N, Wolfman WL; Clinical Practice – Gynaecology Committee. Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol. 2013;35(5):473-5.
• 3. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem. 2006;387(4):365– 72.
• 4. Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A et al. Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumorstroma. Cell Cycle. 2012;11(22):4152-66.
• 5. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121(11):2381–6.
• 6. Ziech D, Franco R, Pappa A, Panayiotidis M. I. Reactive Oxygen Species (ROS)-Induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res. 2011;711(1-2):167–73.
• 7. Comini MA. Measurement and meaning of cellular thiol:disufhide redox status. Free Radic Res. 2016;50(2):246-71.
• 8. Zareba I, Palka J. Prolidase-proline dehydrogenase/proline oxidase-collagen biosynthesis axis as a potential interface of apoptosis/autophagy. Biofactors. 2016;42(4):341-8.
• 9. Surazynski A, Miltyk W, Palka J, Phang JM. Prolidase-dependent regulation of collagen biosynthesis. Amino Acids. 2008;35(4):731–8.
• 10. Yildiz A, Demirbag R, Yilmaz R, Gur M, Altiparmak IH, Akyol S. The association of serum prolidase activity with the presence and severity of coronary artery disease. Coronary Artery Dis. 2008;19(5):319–25.
• 11. Surazynski A, Donald SP, Cooper SK, Whiteside MA, Salnikow K, Liu Y, et al. Extracellular matrix and HIF-1 signaling: the role of prolidase. Int J Cancer. 2008;122(6):1435–40.
• 12. Palka J, Surazynski A, Karna E, Orlowski K, Puchalski Z, Pruszynski K, et al. Prolidase activity disregulation in chronic pancreatitis and pancreatic cancer. Hepatogastroenterology. 2002;49(48):1699–703.
• 13. Cechowska-Pasko M, Pakła J, Wojtukiewicz MZ. Enhanced prolidase activity and decreased collagen content in breast cancer tissue. Int J Exp Pathol. 2006;87(4):289–96.
• 14. Guszczyn T, Sobolewski K. Deregulation of collagen metabolism in human stomach cancer. Pathobiology. 2004;71(6):308–13.
• 15. Karna E, Surazynski A, Palka J. Collagen metabolism disturbances are accompanied by an increase in prolidase activity in lung carcinoma planoepitheliale. Int J Exp Pathol. 2000;81(5):341–7.
• 16. Kayadibi H, Gültepe M, Yasar B, Ince AT, Ozcan O, Ipcioglu OM, et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci. 2009;54(8):1764-71.
• 17. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to imidodipeptiduria. Clinica Chimica Acta. 1982;125(2):193 – 205.
• 18. Chinard FP. Photometric estimation of proline and ornithine. J Biol Chem. 1952;199(1):91–5.
• 19. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103–11.
• 20. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37(2):112–9.
• 21. Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Aksoy N. Assessment of preoperative serum prolidase activity in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):97-100.
• 22. Jussila T, Kauppila S, Bode M, Tapanainen J, Risteli J, Risteli L et al. Synthesis and maturation of type I and type III collagens in endometrial adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 2004;115(1):66-74.
• 23. Arioz DT, Camuzcuoglu H, Toy H, Kurt S, Celik H, Aksoy N. Serum prolidase activity in patients with stage I endometrial cancer. Int J Gynecol Cancer. 2009;19(7):1244-7.
• 24. Surazynski A, Sienkiewicz P, Wolczynski S, Palka J. Differential effects of echistatin and thrombin on collagen production and prolidase activity in human dermal fibroblasts and their possible implication in beta1-integrin mediated signaling. Pharmacol Res. 2005;51(3):217–21.
• 25. Wójcik-Krowiranda K, Forma E, Zaczek A, Bryś M, Anna MK, Bieńkiewicz A. Expression of E-cadherin and beta1-integrin mRNA in endometrial cancer. Ginekol Pol. 2013;84(11):910-4.
• 26. Moro L, Greco M, Maiorano E, Selvaggi L, Marra E, Perlino E. Transcriptional regulation of beta1 integrin expression in the physio/pathological states of human endometrial tissues. Int J Oncol. 2005;26(2):457-65.
• 27. Manoharan S, Kolanjiappan K, Kayalvizhi M. Enhanced lipid peroxidation and impaired enzymic antioxidant activities in the erythrocytes of patients with cervical carcinoma. Cell Mol Biol Lett. 2004;9(4A):699- 707.
• 28. Pejić S, Kasapović J, Todorović A, Stojiljković V, Pajović SB. Lipid peroxidation and antioxidant status in blood of patients with uterine myoma, endometrial polypus, hyperplastic and malignant endometrium. Biol Res. 2006;39(4):619-29.
• 29. Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Erel O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;112(3):481-5.
• 30. Vural M, Camuzcuoglu H, Toy H, Camuzcuoglu A, Aksoy N. Oxidative stress and prolidase activity in women with uterine fibroids. J Obstet Gynaecol. 2012;32(1):68-72.